TFX · Teleflex Inc
$139.67
+1.96 (+1.42%)
At close · Aug 28
Market Cap
$5.92B
Shares
42.37M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$139.67
Open$137.35
Day$137.35–140.57
52W close$100.34–140.18
Avg vol 30d572K
Short int4.8M · 11.4% float · 6.4d
Short vol68%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+14%
above
Price vs 50-day avg
+4%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
99%
near high
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+23%
trailing
YTD return
+14%
this year
Relative strength
+10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $134 › 200d $122 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +69 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.41% of float · ▲ +59.7% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
383 holders — mid 3-yr range
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
Gross margin
56%
contracting
EPS growth
−1468%
Y/Y
Buyback
$1.0B
authorized
Balance sheet
$2.3B
net debt
Quant / Vol
risk profile
Volatility
40%
annualized · 1-yr
Max drawdown
−25%
past year
ATR
2.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
full year 2026
GAAP revenue growth from continuing operations
Initiated
13.4% – 14.4%
GAAP diluted earnings per share from continuing operations
Lowered
$2.54 – $2.84
May 7, 2026
$2.90 – $3.20
changed to
Aug 6, 2026
$2.54 – $2.84
prior FY $-20.25
midpoint +113.3% Y/Y
Pro forma adjusted constant currency revenue growth from continu
Lowered
3.5% – 4.5%
May 7, 2026
4.5% – 5.5%
changed to
Aug 6, 2026
3.5% – 4.5%
Adjusted diluted earnings per share from continuing operations
Raised
$6.90 – $7.20
May 7, 2026
$6.25 – $6.55
changed to
Aug 6, 2026
$6.90 – $7.20
Pro forma adjusted constant currency revenue growth
Initiated
3.5% – 4.5%
2026
Adjusted Operating Margin
19%
GAAP revenue growth
13.4% – 14.4%
Prior guidance
period ended
· from the 8-K filed Jan 8, 2026
Revenue
· full year 2025
$3.27B – $3.28B
Guided vs delivered
· last 5 settled
GAAP diluted earnings per share from continuing operations
full year 2025
guided $-4.42 – $-4.22
$-20.25
Miss −368.8%
EPS dilution from Palette
2024
guided $0.35
$1.48
Beat +322.9%
Reported revenue
2023
guided $2.92B – $2.96B
$1.71B
Miss −41.7%
GAAP adjusted earnings per share
2023
guided $8.14 – $8.74
$7.53
Miss −10.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+14%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $134 › 200d $122 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +69 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.41% of float · ▲ +59.7% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
383 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $100
Now $140 · 99%
Range high $140
vs 200-day avg +14%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted EPS non-GAAP | $1.76 | Q2'26 | — |
| adjusted gross margin non-GAAP | 61.7% | Q2'26 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Gross margin 58.2%
+0.3% Restructuring and optimization charges (A)
+3.2% Intangible amortization expense
= Adjusted gross margin 61.7%
|
|||
| adjusted operating margin non-GAAP | 19.6% | Q2'26 | — |
|
|
|||
| Pro forma adjusted revenue non-GAAP | $1.12B | Six Months Ended June 30, 2026 | — |
|
|
|||
| Pro Forma Adjusted Constant Currency Revenue Growth non-GAAP | 5.1% | Three Months Ended March 31, 2026 | — |
| Adjusted constant currency revenue growth non-GAAP | 15.4% | FY 2025 | — |
| Adjusted effective income tax rate non-GAAP | 11.1% | Three Months Ended December 31, 2025 | +26.1% |
|
|
|||
| Adjusted revenue from continuing operations non-GAAP | $1.98B | FY 2025 | — |
| Adjusted revenue from continuing operations growth non-GAAP | 16.3% | FY 2025 | — |
| Continuing operations revenue as adjusted non-GAAP | $1.98B | Year Ended December 31, 2025 | — |
| Interventional Pro forma adjusted constant currency revenue growth non-GAAP | 8.1% | 2H 2025 | — |
| Interventional Pro forma adjusted revenue non-GAAP | $834.5M | FY 2025 | — |
| Surgical Pro forma adjusted constant currency revenue growth non-GAAP | 3.2% | 2H 2025 | — |
| Surgical Pro forma adjusted revenue non-GAAP | $416.1M | FY 2025 | — |
| Vascular Pro forma adjusted constant currency revenue growth non-GAAP | 2.4% | 2H 2025 | — |
| Vascular Pro forma adjusted revenue non-GAAP | $917.7M | FY 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TFX
this stock
Teleflex Inc
|
$5.92B | +14.4% | +17.2% | — | 11.4% |
|
ISRG
Intuitive Surgical Inc
|
$129.68B | -34.2% | +20.5% | 42.1 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$51.62B | — | +8.2% | — | 3.4% |
|
MDLN
Medline Inc.
|
$45.55B | -16.0% | +11.5% | — | 2.8% |
|
ALC
Alcon Inc
|
$34.81B | -8.6% | +10.5% | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TFX | +0.6% | +2.2% | +22.9% | +2.2% | +14.5% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +0.1% | -0.8% | +9.5% | -0.8% | +1.6% |
Capital returns
Latest dividend
$0.34
/ share · ex Aug 14, 2026
Paid (TTM)
$1.36
/ share · 4 payouts
Dividend yield (TTM, derived)
0.97%
Buyback program
· as of Aug 7, 2026
Authorized
$1.00B
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
96943
CUSIP
879369106
13F (30d)
306 filings
294 filers
Visit website
Investor relations